Quarterly report [Sections 13 or 15(d)]

License Agreements (Avenue) (Details)

v3.25.2
License Agreements (Avenue) (Details) - Avenue
 1 Months Ended
Apr. 24, 2025
USD ($)
Feb. 28, 2023
USD ($)
item
Jul. 31, 2025
USD ($)
May 31, 2025
USD ($)
AnnJi License Agreement        
License Agreements        
Upfront fees paid   $ 3,000,000    
Number of tranches of shares | item   2    
AnnJi License Agreement | Maximum        
License Agreements        
Reimbursement payable in connection with clinical trial   $ 10,800,000    
Development milestone payable, US   14,500,000    
Development milestone payable, outside US   27,500,000    
Sales milestone payable   165,000,000    
Annual net sales as basis for milestone payments   750,000,000    
AnnJi License Agreement | Minimum        
License Agreements        
Annual net sales as basis for milestone payments   $ 75,000,000    
Termination and Transfer Agreement        
License Agreements        
Period Not To Compete 48 months      
Share repurchase, amount paid $ 1      
Legal expense reimbursed 200,000      
Termination payments receivable $ 1,600,000      
Termination paid       $ 800,000
Percentage of royalty on future net sales 1.75%      
Percentage to be received on third party licensing revenue 15.00%      
Termination and Transfer Agreement | Maximum        
License Agreements        
Development and regulatory milestone payments receivable $ 5,000,000      
Sales milestone payments receivable 17,000,000      
Maximum amounts to be received on third party licensing revenue 7,500,000      
Termination and Transfer Agreement | Minimum        
License Agreements        
Maximum amounts to be received on third party licensing revenue $ 4,000,000      
Subsequent events | Termination and Transfer Agreement        
License Agreements        
Termination paid     $ 800,000